Skip to main content

Advertisement

Log in

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Tyrosine kinase inhibitor (TKI)-induced thyroid dysfunction has been identified as an important but manageable adverse effect of targeted therapy. Several studies have suggested that patients who develop hypothyroidism respond better to TKIs, but this relationship is not well elucidated. We evaluated the relationship between new-onset hypothyroidism and clinical response in patients with advanced cancers treated with TKIs at our institution.

Methods

We retrospectively reviewed records for patients from four clinical trials that included at least one TKI  therapy between January 2006 and December 2011. Patients with preexisting thyroid disease, including thyroid cancer, hypothyroidism, or hyperthyroidism, were excluded. Analysis of 197 patients was performed. Response was determined using RECIST 1.0. Clinical benefit was described as complete response, partial response, or stable disease greater than 4 months. Multivariable logistic regression analysis was performed to correlate patient characteristics with clinical response.

Results

The median age for the 197 patients was 58 years (range, 13–85 years), and 56 % were female. Of the 197 patients, 52 (26 %) developed hypothyroidism after therapy. Clinical benefit rates were 50 % in patients with new-onset hypothyroidism versus 34 % in patients without hypothyroidism. In the univariate model, the odds ratio (OR) for new-onset hypothyroidism was 1.9 [95 % confidence interval (CI) (1.0, 3.6) and p = 0.05]. We grouped tumor types into six categories (breast, colorectal carcinoma, melanoma, non-small cell lung cancer, pancreas, and other). When adjusted for tumor type, age (>50 years) and sex, the OR was 2.9 [95 % CI (1.3, 6.5) and p = 0.012] for new-onset hypothyroidism.

Conclusion

New-onset hypothyroidism was associated with favorable clinical response in patients who received TKI treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brown RL (2011) Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol 6(4):217–226. doi:10.1007/s11523-011-0197-2

    Article  PubMed  Google Scholar 

  2. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99(1):81–83. doi:10.1093/jnci/djk008

    Article  CAS  PubMed  Google Scholar 

  3. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17(4):351–355. doi:10.1089/thy.2006.0308

    Article  CAS  PubMed  Google Scholar 

  4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145(9):660–664

    Article  PubMed  Google Scholar 

  5. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92(9):3531–3534. doi:10.1210/jc.2007-0586

    Article  CAS  PubMed  Google Scholar 

  6. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117(3):534–544. doi:10.1002/cncr.25422

    Article  PubMed  Google Scholar 

  7. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, Thielen B, Herrmann E (2011) Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 29(6):807–813. doi:10.1007/s00345-010-0627-2

    Article  CAS  PubMed  Google Scholar 

  8. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Sazawa A, Kanayama H, Nonomura K (2009) Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib? J Clin Oncol 27:(suppl: abstr e16097)

  9. Wolter P, Stefan C, Decallonne B, Dumez H, Fieuws S, Wildiers H, Clement P, Debaere D, Van Oosterom A, Schoffski P (2008) Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol 26:(suppl: abstr 16145)

  10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  CAS  PubMed  Google Scholar 

  11. Shah DR, Shah RR, Morganroth J (2013) Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 36(6):413–426. doi:10.1007/s40264-013-0050-x

    Article  CAS  PubMed  Google Scholar 

  12. Makita N, Iiri T (2013) Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23(2):151–159. doi:10.1089/thy.2012.0456

    Article  CAS  PubMed  Google Scholar 

  13. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P (2009) Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160(3):331–336. doi:10.1530/EJE-08-0648

    Article  CAS  PubMed  Google Scholar 

  14. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6(4):219–228. doi:10.1038/nrclinonc.2009.4

    Article  CAS  PubMed  Google Scholar 

  15. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78(4):433–438. doi:10.1016/j.clpt.2005.06.010

    Article  PubMed  Google Scholar 

  16. Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4(5):560–575. doi:10.3978/j.issn.2218-6751.2015.06.06

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2):227–230. doi:10.1093/annonc/mdn637

    Article  CAS  PubMed  Google Scholar 

  18. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26(22):3743–3748. doi:10.1200/JCO.2007.15.5416

    Article  CAS  PubMed  Google Scholar 

  19. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F (2011) An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 16(9):1325–1332. doi:10.1634/theoncologist.2010-0002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A (2014) Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Investig New Drugs 32(4):717–722. doi:10.1007/s10637-014-0104-7

    Article  CAS  Google Scholar 

  21. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A (2014) Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 19(4):426–428. doi:10.1634/theoncologist.2013-0231

    Article  PubMed  PubMed Central  Google Scholar 

  22. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A (2015) The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist 20(7):737–741. doi:10.1634/theoncologist.2015-0065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was supported by the NIH/NCI under Award Number P30CA016672 and used the Clinical Trials Support Resource. The results of this study were presented in a poster at the American Association for Cancer Research annual meeting in San Diego, CA, on April 7, 2014.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aung Naing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bilen, M.A., Patel, A., Hess, K.R. et al. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol 78, 167–171 (2016). https://doi.org/10.1007/s00280-016-3073-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3073-z

Keywords

Navigation